Physicians' attitudes toward anticoagulant therapy in patients with chronic atrial fibrillation

Kenji Maeda1, Tatsuya Sakai, Kenji Hira

  • 1Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto.

Insights

Physicians in Japan show reluctance towards anticoagulant therapy for atrial fibrillation (AF) patients. Factors like physician experience and patient bleeding risk negatively influence treatment decisions.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Pharmacy

Background:

  • Clinical trials confirm anticoagulant therapy significantly reduces ischemic stroke risk in atrial fibrillation (AF).
  • Despite proven efficacy, physician reluctance to prescribe anticoagulants for chronic AF patients persists in Japan.

Purpose of the Study:

  • To investigate the attitudes of Japanese physicians regarding anticoagulant therapy in patients with chronic atrial fibrillation.
  • To identify factors influencing physician preferences for or against anticoagulant use in AF management.

Main Methods:

  • A survey was conducted at the Japanese Society of General Medicine annual meeting.
  • Physicians evaluated 8 vignettes of chronic AF patients, choosing preferred therapy from 6 options (including warfarin and aspirin).
  • 139 responses were collected from 209 distributed questionnaires (67% response rate).

Main Results:

  • Only 26% of surveyed physicians favored anticoagulant therapy across all patient vignettes.
  • Negative attitudes were associated with longer clinical experience and teaching hospital roles.
  • Positive attitudes linked to prior AF thromboembolism prevention experience and trial influence; patient bleeding risk and advanced age deterred anticoagulant use.

Conclusions:

  • Japanese physicians, particularly experienced ones or those in teaching roles, exhibit a negative stance on anticoagulant therapy for chronic AF.
  • Patient-specific factors like advanced age and bleeding risk significantly deter anticoagulant prescription.
  • Further research is needed to address barriers to optimal anticoagulation in AF management.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...